Modeling of Free Fatty Acid Dynamics: Insulin and Nicotinic Acid Resistance Under Acute and Chronic Treatments
Overview
Authors
Affiliations
Nicotinic acid (NiAc) is a potent inhibitor of adipose tissue lipolysis. Acute administration results in a rapid reduction of plasma free fatty acid (FFA) concentrations. Sustained NiAc exposure is associated with tolerance development (drug resistance) and complete adaptation (FFA returning to pretreatment levels). We conducted a meta-analysis on a rich pre-clinical data set of the NiAc-FFA interaction to establish the acute and chronic exposure-response relations from a macro perspective. The data were analyzed using a nonlinear mixed-effects framework. We also developed a new turnover model that describes the adaptation seen in plasma FFA concentrations in lean Sprague-Dawley and obese Zucker rats following acute and chronic NiAc exposure. The adaptive mechanisms within the system were described using integral control systems and dynamic efficacies in the traditional [Formula: see text] model. Insulin was incorporated in parallel with NiAc as the main endogenous co-variate of FFA dynamics. The model captured profound insulin resistance and complete drug resistance in obese rats. The efficacy of NiAc as an inhibitor of FFA release went from 1 to approximately 0 during sustained exposure in obese rats. The potency of NiAc as an inhibitor of insulin and of FFA release was estimated to be 0.338 and 0.436 [Formula: see text], respectively, in obese rats. A range of dosing regimens was analyzed and predictions made for optimizing NiAc delivery to minimize FFA exposure. Given the exposure levels of the experiments, the importance of washout periods in-between NiAc infusions was illustrated. The washout periods should be [Formula: see text]2 h longer than the infusions in order to optimize 24 h lowering of FFA in rats. However, the predicted concentration-response relationships suggests that higher AUC reductions might be attained at lower NiAc exposures.
Model-based assessment of combination therapies - ranking of radiosensitizing agents in oncology.
Baaz M, Cardilin T, Lignet F, Zimmermann A, El Bawab S, Gabrielsson J BMC Cancer. 2023; 23(1):409.
PMID: 37149596 PMC: 10164338. DOI: 10.1186/s12885-023-10899-y.
Challenge model of TNF turnover at varying LPS and drug provocations.
Held F, Hoppe E, Cvijovic M, Jirstrand M, Gabrielsson J J Pharmacokinet Pharmacodyn. 2019; 46(3):223-240.
PMID: 30778719 PMC: 6529397. DOI: 10.1007/s10928-019-09622-x.
Olafsdottir H, Leander J, Almquist J, Jirstrand M AAPS J. 2018; 20(5):88.
PMID: 30069613 DOI: 10.1208/s12248-018-0232-7.
Assessment of gut microbiota populations in lean and obese Zucker rats.
Hakkak R, Korourian S, Foley S, Erickson B PLoS One. 2017; 12(7):e0181451.
PMID: 28704522 PMC: 5509373. DOI: 10.1371/journal.pone.0181451.